382 related articles for article (PubMed ID: 15149765)
1. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
Kitchener S
Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
[TBL] [Abstract][Full Text] [Related]
2. [Yellow fever].
Wiercińska-Drapało A
Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
[TBL] [Abstract][Full Text] [Related]
3. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
[TBL] [Abstract][Full Text] [Related]
4. Acute viscerotropic disease following vaccination against yellow fever.
Hayes EB
Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
[TBL] [Abstract][Full Text] [Related]
5. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
[TBL] [Abstract][Full Text] [Related]
7. Viscerotropic disease following yellow fever vaccination in Peru.
Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
[TBL] [Abstract][Full Text] [Related]
8. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
9. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
van de Pol EM; Gisolf EH; Richter C
J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
[TBL] [Abstract][Full Text] [Related]
10. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
Barrett AD; Teuwen DE
Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
[TBL] [Abstract][Full Text] [Related]
11. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever: epidemiology and prevention.
Barnett ED
Clin Infect Dis; 2007 Mar; 44(6):850-6. PubMed ID: 17304460
[TBL] [Abstract][Full Text] [Related]
13. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
[TBL] [Abstract][Full Text] [Related]
14. Current status of the Arilvax; yellow fever vaccine.
Barrett AD
Expert Rev Vaccines; 2004 Aug; 3(4):413-20. PubMed ID: 15270646
[TBL] [Abstract][Full Text] [Related]
15. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina.
Pires-Marczeski FC; Martinez VP; Nemirovsky C; Padula PJ
J Med Virol; 2011 Dec; 83(12):2208-12. PubMed ID: 22012730
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
18. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
[TBL] [Abstract][Full Text] [Related]
19. Short report: Incidence of yellow fever vaccine-associated neurotropic disease.
Guimard T; Minjolle S; Polard E; Fily F; Zeller H; Michelet C; Tattevin P
Am J Trop Med Hyg; 2009 Dec; 81(6):1141-3. PubMed ID: 19996449
[TBL] [Abstract][Full Text] [Related]
20. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(30):643-5. PubMed ID: 11787575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
